Copper
- Generic Name
- Copper
- Brand Names
- Paragard T 380a, Vitafol-one, Cuprymina
- Drug Type
- Small Molecule
- Chemical Formula
- Cu
- CAS Number
- 7440-50-8
- Unique Ingredient Identifier
- 789U1901C5
- Background
Copper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase . Copper is commonly used in contraceptive intrauterine devices (IUD) .
- Indication
For use in the supplementation of total parenteral nutrition and in contraception with intrauterine devices .
- Associated Therapies
- Emergency Contraception, IUD therapy, Trace Element Deficiency, Dietary supplementation
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Target Recruit Count
- 8
- Registration Number
- NCT06736054
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Irvine, California, United States
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer
- Conditions
- Prostate CancerProstate AdenocarcinomaBiochemical Recurrence of Malignant Neoplasm of Prostate
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 235
- Registration Number
- NCT06235099
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Tower Urology, Los Angeles, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
- Conditions
- Prostate AdenocarcinomaProstate Cancer
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- Curium US LLC
- Target Recruit Count
- 323
- Registration Number
- NCT06235151
- Locations
- 🇺🇸
UNC Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸Fred Hutchinson Cancer Center, Seattle, Washington, United States
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Digestive System Neuroendocrine Tumor G2Digestive System Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine NeoplasmMetastatic Malignant Neoplasm in the LiverPancreatic Neuroendocrine Tumor G1
- Interventions
- Procedure: Tumor DebulkingProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT06016855
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation
- Conditions
- Metastatic Malignant Solid Neoplasm
- Interventions
- Procedure: Positron Emission TomographyRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT05728372
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
- Conditions
- Stage IIIB Rectal Cancer AJCC v8Stage IIIC Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Locally Advanced Rectal Carcinoma
- Interventions
- Procedure: Imaging Technique
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT05245786
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Impact of Contraceptives on Cervico-Vaginal Mucosa
- Conditions
- Contraceptive; Complications, IntrauterineMucosal Inflammation
- Interventions
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 112
- Registration Number
- NCT04814927
- Locations
- 🇺🇸
Eastern Virginia Medical School, Norfolk, Virginia, United States
🇰🇪KEMRI, Thika, Central, Kenya
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- National Cancer Institute, Slovakia
- Registration Number
- NCT04265274
- Locations
- 🇸🇰
National Cancer Institute, Bratislava, Slovakia
Copper Histidinate Treatment for Menkes Disease
- Conditions
- Menkes Disease
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Sentynl Therapeutics, Inc.
- Registration Number
- NCT04074512
64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy
- Conditions
- CalcificationBreast Carcinoma
- Interventions
- Procedure: Computed TomographyOther: Pharmacokinetic StudyProcedure: Positron Emission Tomography
- First Posted Date
- 2018-05-31
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT03542695
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.